US3906092A
(en)
|
1971-11-26 |
1975-09-16 |
Merck & Co Inc |
Stimulation of antibody response
|
US6133433A
(en)
|
1984-07-27 |
2000-10-17 |
City Of Hope |
Method for detection and prevention of human cytomegalovirus infection
|
US6242567B1
(en)
|
1984-07-27 |
2001-06-05 |
City Of Hope |
Method for detection and prevention of human cytomegalovirus infection
|
US6162620A
(en)
|
1986-03-07 |
2000-12-19 |
Cogent Limited |
Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor
|
CA1335429C
(en)
*
|
1986-03-07 |
1995-05-02 |
Geoffrey L. Smith |
Processes for the production of hcmv glycoproteins, antibodies thereto and hcmv vaccines, and recombinant vectors therefor
|
US6207161B1
(en)
|
1986-07-16 |
2001-03-27 |
City Of Hope |
Induction of cytolytic T-lymphocytes with cytomegalovirus polypeptides
|
DE69032284T2
(de)
|
1989-03-21 |
1998-10-08 |
Vical Inc |
Expression von exogenen polynukleotidsequenzen in wirbeltieren
|
WO1993014778A1
(en)
|
1992-01-23 |
1993-08-05 |
Vical, Inc. |
Ex vivo gene transfer
|
IL112820A0
(en)
|
1994-03-07 |
1995-05-26 |
Merck & Co Inc |
Coordinate in vivo gene expression
|
WO1995026204A1
(en)
|
1994-03-25 |
1995-10-05 |
Isis Pharmaceuticals, Inc. |
Immune stimulation by phosphorothioate oligonucleotide analogs
|
CA2191362A1
(en)
|
1994-06-02 |
1995-12-14 |
Mark Selby |
Nucleic acid immunization using a virus-based infection/transfection system
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
EP0914441A2
(en)
|
1996-04-23 |
1999-05-12 |
The Wistar Institute Of Anatomy And Biology |
Novel human cytomegalovirus dna constructs and uses therefor
|
US6214966B1
(en)
|
1996-09-26 |
2001-04-10 |
Shearwater Corporation |
Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
|
US6074645A
(en)
|
1996-11-12 |
2000-06-13 |
City Of Hope |
Immuno-reactive peptide CTL epitopes of human cytomegalovirus
|
US6156317A
(en)
|
1996-11-12 |
2000-12-05 |
City Of Hope |
Immuno-reactive peptide CTL epitopes of human cytomegalovirus
|
US6562345B1
(en)
|
1996-11-12 |
2003-05-13 |
City Of Hope |
Immuno-reactive peptide CTL epitopes of human cytomegalovirus
|
EP0855184A1
(en)
|
1997-01-23 |
1998-07-29 |
Grayson B. Dr. Lipford |
Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
|
US20030073640A1
(en)
|
1997-07-23 |
2003-04-17 |
Ribozyme Pharmaceuticals, Inc. |
Novel compositions for the delivery of negatively charged molecules
|
AU750106B2
(en)
|
1997-10-07 |
2002-07-11 |
University Of Maryland Biotechnology Institute |
Method for introducing and expressing RNA in animal cells
|
WO1999033982A2
(en)
|
1997-12-23 |
1999-07-08 |
Chiron Corporation |
Human genes and gene expression products i
|
DE19910044A1
(de)
|
1999-03-08 |
2000-09-14 |
Bodo Plachter |
Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff
|
US6514948B1
(en)
|
1999-07-02 |
2003-02-04 |
The Regents Of The University Of California |
Method for enhancing an immune response
|
ATE289630T1
(de)
|
1999-09-09 |
2005-03-15 |
Curevac Gmbh |
Transfer von mrnas unter verwendung von polykationischen verbindungen
|
WO2001023002A1
(en)
|
1999-09-30 |
2001-04-05 |
National Jewish Medical And Research Center |
Method for inhibition of pathogenic microorganisms
|
US6632435B1
(en)
|
1999-10-20 |
2003-10-14 |
City Of Hope |
CTL epitope analogs
|
US7060291B1
(en)
|
1999-11-24 |
2006-06-13 |
Transave, Inc. |
Modular targeted liposomal delivery system
|
US6835383B2
(en)
|
2000-03-23 |
2004-12-28 |
City Of Hope |
Protein kinase deficient, immunologically active CMVpp65 mutants
|
US6998115B2
(en)
|
2000-10-10 |
2006-02-14 |
Massachusetts Institute Of Technology |
Biodegradable poly(β-amino esters) and uses thereof
|
AU2002214624A1
(en)
|
2000-10-20 |
2002-05-06 |
City Of Hope |
Immunoreactive peptide ctl epitopes of human cytomegalovirus pp150
|
US7204990B1
(en)
|
2000-11-28 |
2007-04-17 |
Medimmune Vaccines, Inc. |
Attenuation of cytomegalovirus virulence
|
US7708915B2
(en)
|
2004-05-06 |
2010-05-04 |
Castor Trevor P |
Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein
|
EP1800697B1
(de)
|
2001-06-05 |
2010-04-14 |
CureVac GmbH |
Stabilisierte mRNA mit erhöhtem G/C-Gehalt für die Gentherapie
|
WO2003011443A2
(en)
|
2001-07-27 |
2003-02-13 |
President And Fellows Of Harvard College |
Laminar mixing apparatus and methods
|
CA2462593A1
(en)
|
2001-10-03 |
2003-04-10 |
Kam W. Leong |
Compositions for oral gene therapy and methods of using same
|
DE10162480A1
(de)
|
2001-12-19 |
2003-08-07 |
Ingmar Hoerr |
Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
|
WO2003059381A2
(en)
*
|
2002-01-18 |
2003-07-24 |
Curevac Gmbh |
Immunogenic preparations and vaccines on the basis of mrna
|
US20050222064A1
(en)
|
2002-02-20 |
2005-10-06 |
Sirna Therapeutics, Inc. |
Polycationic compositions for cellular delivery of polynucleotides
|
WO2003092665A2
(en)
|
2002-05-02 |
2003-11-13 |
Massachusetts Eye And Ear Infirmary |
Ocular drug delivery systems and use thereof
|
DE10229872A1
(de)
|
2002-07-03 |
2004-01-29 |
Curevac Gmbh |
Immunstimulation durch chemisch modifizierte RNA
|
ES2429338T3
(es)
*
|
2002-12-23 |
2013-11-14 |
Vical Incorporated |
Vacuna basada en polinucleótidos optimizados por codones contra infección por citomegalovirus humano
|
US20040228842A1
(en)
*
|
2003-02-27 |
2004-11-18 |
Shan Lu |
Compositions and methods for cytomegalovirus treatment
|
WO2004093905A1
(en)
|
2003-04-16 |
2004-11-04 |
City Of Hope |
Human cytomegalovirus antigens expressed in mva and methods of use
|
EP1636385A4
(en)
|
2003-06-24 |
2010-06-02 |
Mirus Bio Corp |
INHIBITION OF GENE FUNCTION BY IN VIVO DISTRIBUTION OF GENE EXPRESSION INHIBITORS BASED ON POLYNUCLEOTIDES IN MAMMALIAN CELLS
|
PT1651666E
(pt)
|
2003-07-11 |
2009-08-28 |
Alphavax Inc |
Vacinas de citomegalovírus à base de alfavírus
|
DE10335833A1
(de)
|
2003-08-05 |
2005-03-03 |
Curevac Gmbh |
Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
|
EP1675614A2
(en)
|
2003-10-11 |
2006-07-05 |
Inex Pharmaceuticals Corp. |
Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
|
WO2005072710A2
(en)
|
2004-01-28 |
2005-08-11 |
Johns Hopkins University |
Drugs and gene carrier particles that rapidly move through mucous barriers
|
US20050232981A1
(en)
|
2004-04-15 |
2005-10-20 |
Ben-Sasson Shmuel A |
Compositions capable of facilitating penetration across a biological barrier
|
DE102004035227A1
(de)
|
2004-07-21 |
2006-02-16 |
Curevac Gmbh |
mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
|
DE102004042546A1
(de)
|
2004-09-02 |
2006-03-09 |
Curevac Gmbh |
Kombinationstherapie zur Immunstimulation
|
WO2006056027A1
(en)
*
|
2004-11-29 |
2006-06-01 |
The Council Of The Queensland Institute Of Medical Research |
Human cytomegalovirus immunotherapy
|
EP1856179B1
(en)
|
2004-12-10 |
2013-05-15 |
Kala Pharmaceuticals, Inc. |
Functionalized poly (ether-anhydride) block copolymers
|
US9068969B2
(en)
|
2004-12-28 |
2015-06-30 |
Ptc Therapeutics, Inc. |
Cell based methods and systems for the identification of RNA regulatory sequences and compounds that modulate their functions
|
US8192718B1
(en)
|
2005-01-04 |
2012-06-05 |
Gp Medical, Inc. |
Pharmaceutical composition of nanoparticles
|
US7404969B2
(en)
|
2005-02-14 |
2008-07-29 |
Sirna Therapeutics, Inc. |
Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
|
WO2007086883A2
(en)
|
2005-02-14 |
2007-08-02 |
Sirna Therapeutics, Inc. |
Cationic lipids and formulated molecular compositions containing them
|
EP2290363B1
(en)
|
2005-03-11 |
2014-01-08 |
Firalis SAS |
Biomarkers for cardiovascular side-effects induced by cox-2 inhibitory compounds
|
US7638558B2
(en)
|
2005-04-01 |
2009-12-29 |
Intezyne Technologies, Inc. |
Polymeric micelles for drug delivery
|
EP1885403B1
(en)
|
2005-04-12 |
2013-05-08 |
Nektar Therapeutics |
Poly(ethyleneglycol) conjugates of Lysostaphin
|
PL2279758T3
(pl)
|
2005-06-16 |
2015-07-31 |
Nektar Therapeutics |
Koniugaty mające degradowalne połączenie oraz odczynniki polimerowe użyteczne w wytwarzaniu takich koniugatów
|
LT2578685T
(lt)
|
2005-08-23 |
2019-06-10 |
The Trustees Of The University Of Pennsylvania |
Rnr, apimančios modifikuotus nukleozidus ir jų panaudojimo būdai
|
CA2628300C
(en)
*
|
2005-11-02 |
2018-04-17 |
Protiva Biotherapeutics, Inc. |
Modified sirna molecules and uses thereof
|
DE102006007433A1
(de)
|
2006-02-17 |
2007-08-23 |
Curevac Gmbh |
Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure
|
EP1986695B1
(en)
|
2006-02-21 |
2015-06-03 |
Nektar Therapeutics |
Segmented degradable polymers and conjugates made therefrom
|
JP5630998B2
(ja)
|
2006-05-15 |
2014-11-26 |
マサチューセッツ インスティテュート オブ テクノロジー |
機能的粒子のためのポリマー
|
WO2007146024A2
(en)
|
2006-06-07 |
2007-12-21 |
The Trustees Of Princeton University |
Cytomegalovirus surface protein complex for use in vaccines and as a drug target
|
AU2007280690C1
(en)
|
2006-07-31 |
2012-08-23 |
Curevac Gmbh |
Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant
|
ATE498393T1
(de)
|
2006-09-08 |
2011-03-15 |
Univ Johns Hopkins |
Zusammensetzungen zur transportintensivierung durch die schleimhaut
|
DE102006051516A1
(de)
|
2006-10-31 |
2008-05-08 |
Curevac Gmbh |
(Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
|
ES2447516T3
(es)
|
2006-12-21 |
2014-03-12 |
Stryker Corporation |
Formulaciones de liberación sostenida que comprenden cristales BMP-7
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
CA2689042A1
(en)
|
2007-02-16 |
2008-08-28 |
Merck & Co., Inc. |
Compositions and methods for potentiated activity of biologicaly active molecules
|
WO2009030254A1
(en)
|
2007-09-04 |
2009-03-12 |
Curevac Gmbh |
Complexes of rna and cationic peptides for transfection and for immunostimulation
|
ES2376175T3
(es)
|
2007-09-28 |
2012-03-09 |
Bind Biosciences, Inc. |
Direccionamiento a células de c�?ncer usando nanopart�?culas.
|
WO2009046739A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating prostate cancer (pca)
|
WO2009046738A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
|
EP3346005A1
(en)
|
2008-01-31 |
2018-07-11 |
CureVac AG |
Nucleic acids of formula (i) (nuglxmgnnv)a and derivatives thereof as an immunostimulating agent/adjuvant
|
PL2279254T3
(pl)
*
|
2008-04-15 |
2017-11-30 |
Protiva Biotherapeutics Inc. |
Nowe preparaty lipidowe do dostarczania kwasów nukleinowych
|
WO2009127230A1
(en)
|
2008-04-16 |
2009-10-22 |
Curevac Gmbh |
MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
|
EP2309991B1
(en)
|
2008-06-16 |
2019-03-06 |
Pfizer Inc |
Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
|
US8613951B2
(en)
|
2008-06-16 |
2013-12-24 |
Bind Therapeutics, Inc. |
Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
|
SI2774608T1
(sl)
|
2008-06-16 |
2020-02-28 |
Pfizer Inc. |
Polimerni nanodelci, napolnjeni z zdravilom, ter postopki za njihovo pripravo in uporabo
|
HUE035770T2
(en)
|
2008-06-16 |
2018-05-28 |
Pfizer |
Process for the preparation of diblock copolymers functionalized with targeting material for use in the preparation of therapeutic nanoparticles
|
EP2303319B1
(en)
|
2008-06-20 |
2016-10-05 |
Duke University |
Compositions, methods and kits for eliciting an immune response
|
WO2010021865A1
(en)
|
2008-08-18 |
2010-02-25 |
Merck Sharp & Dohme Corp. |
Novel lipid nanoparticles and novel components for delivery of nucleic acids
|
WO2010030763A2
(en)
|
2008-09-10 |
2010-03-18 |
Bind Biosciences, Inc. |
High throughput fabrication of nanoparticles
|
WO2010037408A1
(en)
|
2008-09-30 |
2010-04-08 |
Curevac Gmbh |
Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
|
EP2350043B9
(en)
*
|
2008-10-09 |
2014-08-20 |
TEKMIRA Pharmaceuticals Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
AU2015210364B2
(en)
|
2008-10-09 |
2017-03-09 |
Arbutus Biopharma Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
EP2902013A1
(en)
|
2008-10-16 |
2015-08-05 |
Marina Biotech, Inc. |
Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics
|
MX353900B
(es)
|
2008-11-07 |
2018-02-01 |
Massachusetts Inst Technology |
Lipidoides de aminoalcohol y usos de los mismos.
|
KR102264822B1
(ko)
|
2008-11-10 |
2021-06-14 |
알닐람 파마슈티칼스 인코포레이티드 |
치료제 운반용 신규 지질 및 조성물
|
WO2010057203A2
(en)
|
2008-11-17 |
2010-05-20 |
The Board Of Regents Of The University Of Texas System |
Hdl particles for delivery of nucleic acids
|
EP2379064B1
(en)
|
2008-12-15 |
2020-02-26 |
Pfizer Inc. |
Long circulating nanoparticles for sustained release of therapeutic agents
|
WO2010080724A1
(en)
|
2009-01-12 |
2010-07-15 |
Merck Sharp & Dohme Corp. |
Novel lipid nanoparticles and novel components for delivery of nucleic acids
|
US20120101148A1
(en)
|
2009-01-29 |
2012-04-26 |
Alnylam Pharmaceuticals, Inc. |
lipid formulation
|
WO2010088927A1
(en)
|
2009-02-09 |
2010-08-12 |
Curevac Gmbh |
Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds
|
JP5622254B2
(ja)
|
2009-03-31 |
2014-11-12 |
国立大学法人東京大学 |
二本鎖リボ核酸ポリイオンコンプレックス
|
WO2010127159A2
(en)
|
2009-04-30 |
2010-11-04 |
Intezyne Technologies, Incorporated |
Polymeric micelles for polynucleotide encapsulation
|
US8580276B2
(en)
|
2009-06-05 |
2013-11-12 |
City Of Hope |
Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
|
WO2010148085A1
(en)
|
2009-06-16 |
2010-12-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Rna nanoparticles and methods of use
|
JP5766188B2
(ja)
|
2009-07-01 |
2015-08-19 |
プロチバ バイオセラピューティクス インコーポレイティッド |
固形腫瘍に治療剤を送達するための脂質製剤
|
WO2011000106A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Improved cationic lipids and methods for the delivery of therapeutic agents
|
WO2011005799A2
(en)
|
2009-07-06 |
2011-01-13 |
Novartis Ag |
Self replicating rna molecules and uses thereof
|
ES2579936T3
(es)
|
2009-08-20 |
2016-08-17 |
Sirna Therapeutics, Inc. |
Nuevos lípidos catiónicos con diversos grupos de cabeza para el suministro oligonucleotídico
|
US20110053829A1
(en)
|
2009-09-03 |
2011-03-03 |
Curevac Gmbh |
Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
|
WO2011043913A2
(en)
|
2009-10-08 |
2011-04-14 |
Merck Sharp & Dohme Corp. |
Novel cationic lipids with short lipid chains for oligonucleotide delivery
|
CA2816925C
(en)
|
2009-11-04 |
2023-01-10 |
The University Of British Columbia |
Nucleic acid-containing lipid particles and related methods
|
RS58405B1
(sr)
|
2009-12-01 |
2019-04-30 |
Translate Bio Inc |
Stereoidni derivati za isporuku irnk u humanim genetskim oboljenjima
|
WO2011069529A1
(en)
|
2009-12-09 |
2011-06-16 |
Curevac Gmbh |
Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
|
WO2011084521A2
(en)
|
2009-12-15 |
2011-07-14 |
Bind Biosciences, Inc. |
Therapeutic polymeric nanoparticles comprising epothilone and methods of making and using same
|
US9295649B2
(en)
|
2009-12-15 |
2016-03-29 |
Bind Therapeutics, Inc. |
Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
|
EA201290497A1
(ru)
|
2009-12-15 |
2013-01-30 |
Байнд Байосайенсиз, Инк. |
Терапевтические полимерные наночастицы, включающие кортикостероиды, и способы получения таковых
|
US20130116419A1
(en)
|
2010-01-22 |
2013-05-09 |
Daniel Zewge |
Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry
|
WO2012082165A1
(en)
|
2010-01-24 |
2012-06-21 |
Novartis Ag |
Irradiated biodegradable polymer microparticles
|
WO2011119262A1
(en)
|
2010-03-26 |
2011-09-29 |
Cerulean Pharma Inc. |
Methods and systems for generating nanoparticles
|
MY162335A
(en)
|
2010-04-06 |
2017-06-15 |
Vakzine Projekt Man Gmbh |
Viral particle released after infection of mammalian cells by human cytomegalovirus (hcmv) containing a fusion protein and use thereof
|
WO2011127255A1
(en)
|
2010-04-08 |
2011-10-13 |
Merck Sharp & Dohme Corp. |
Preparation of lipid nanoparticles
|
US20110262491A1
(en)
|
2010-04-12 |
2011-10-27 |
Selecta Biosciences, Inc. |
Emulsions and methods of making nanocarriers
|
US20130156845A1
(en)
|
2010-04-29 |
2013-06-20 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
WO2011143230A1
(en)
|
2010-05-10 |
2011-11-17 |
Alnylam Pharmaceuticals |
Methods and compositions for delivery of active agents
|
EP2569276B1
(en)
|
2010-05-12 |
2021-02-24 |
Arbutus Biopharma Corporation |
Novel cationic lipids and methods of use thereof
|
EP2387999A1
(en)
|
2010-05-21 |
2011-11-23 |
CureVac GmbH |
Histidine-containing solution for transfection and/or injection of nucleic acids and uses thereof
|
US8802863B2
(en)
|
2010-05-24 |
2014-08-12 |
Sirna Therapeutics, Inc. |
Amino alcohol cationic lipids for oligonucleotide delivery
|
EP2575767B1
(en)
|
2010-06-04 |
2017-01-04 |
Sirna Therapeutics, Inc. |
Novel low molecular weight cationic lipids for oligonucleotide delivery
|
WO2011163483A2
(en)
|
2010-06-25 |
2011-12-29 |
Massachusetts Institute Of Technology |
Polymers for biomaterials and therapeutics
|
WO2012006369A2
(en)
*
|
2010-07-06 |
2012-01-12 |
Novartis Ag |
Immunisation of large mammals with low doses of rna
|
PT2590676T
(pt)
*
|
2010-07-06 |
2016-11-04 |
Glaxosmithkline Biologicals Sa |
Partículas de transferência de tipo virião para moléculas de arn auto-replicante
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
CA2801523C
(en)
|
2010-07-30 |
2021-08-03 |
Curevac Gmbh |
Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
|
EP3578205A1
(en)
|
2010-08-06 |
2019-12-11 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
WO2012019630A1
(en)
|
2010-08-13 |
2012-02-16 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
|
US20120225129A1
(en)
|
2010-08-20 |
2012-09-06 |
Cerulean Pharma Inc. |
Conjugates, particles, compositions, and related methods
|
US20120058153A1
(en)
*
|
2010-08-20 |
2012-03-08 |
Selecta Biosciences, Inc. |
Synthetic nanocarrier vaccines comprising proteins obtained or derived from human influenza a virus hemagglutinin
|
PT4043040T
(pt)
|
2010-08-31 |
2023-03-24 |
Glaxosmithkline Biologicals Sa |
Lipossomas pequenos para entrega de arn que codifica um imunogénio
|
PL3981427T3
(pl)
|
2010-08-31 |
2022-09-19 |
Glaxosmithkline Biologicals S.A. |
Pegylowane liposomy do dostarczania rna kodującego immunogen
|
US20130164289A1
(en)
|
2010-09-09 |
2013-06-27 |
Virginia Commonwealth University |
Human cytomegalovirus vaccine
|
US10307372B2
(en)
|
2010-09-10 |
2019-06-04 |
The Johns Hopkins University |
Rapid diffusion of large polymeric nanoparticles in the mammalian brain
|
US8466122B2
(en)
|
2010-09-17 |
2013-06-18 |
Protiva Biotherapeutics, Inc. |
Trialkyl cationic lipids and methods of use thereof
|
BR112013004585B1
(pt)
|
2010-09-20 |
2021-09-08 |
Merck Sharp & Dohme Corp |
Lipídeo catiônico, composição de lnp, e, uso de um lipídeo catiônico
|
CA2811430A1
(en)
|
2010-09-30 |
2012-04-05 |
Merck Sharp & Dohme Corp. |
Low molecular weight cationic lipids for oligonucleotide delivery
|
HUE058896T2
(hu)
|
2010-10-01 |
2022-09-28 |
Modernatx Inc |
N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
|
TR201903651T4
(tr)
*
|
2010-10-11 |
2019-04-22 |
Glaxosmithkline Biologicals Sa |
Antijen uygulama platformları.
|
CN103153347A
(zh)
|
2010-10-21 |
2013-06-12 |
默沙东公司 |
用于寡核苷酸递送的新型低分子量阳离子脂质
|
EA201390600A1
(ru)
|
2010-10-22 |
2013-09-30 |
Байнд Терапьютикс, Инк. |
Терапевтические наночастицы с сополимерами с большим молекулярным весом
|
DK2635265T3
(en)
|
2010-11-05 |
2018-07-16 |
Sirna Therapeutics Inc |
New low molecular weight cyclic amine-containing cationic lipids for oligonucleotide delivery
|
CA3054532C
(en)
|
2010-11-05 |
2022-07-12 |
The Johns Hopkins University |
Compositions and methods relating to reduced mucoadhesion
|
AU2012207606B2
(en)
|
2011-01-11 |
2017-02-23 |
Alnylam Pharmaceuticals, Inc. |
Pegylated lipids and their use for drug delivery
|
WO2012099805A2
(en)
|
2011-01-19 |
2012-07-26 |
Ocean Nanotech, Llc |
Nanoparticle based immunological stimulation
|
EA033467B1
(ru)
|
2011-01-31 |
2019-10-31 |
Univ Pennsylvania |
Молекула нуклеиновой кислоты для индукции иммунного ответа против герпесвируса и ее применение
|
US20140066363A1
(en)
|
2011-02-07 |
2014-03-06 |
Arun K. Bhunia |
Carbohydrate nanoparticles for prolonged efficacy of antimicrobial peptide
|
WO2012116715A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in newborns and infants
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
ES2820369T3
(es)
|
2011-03-31 |
2021-04-20 |
Ingell Tech Holding B V |
Composiciones biodegradables adecuadas para liberación controlada
|
WO2012131106A1
(en)
|
2011-03-31 |
2012-10-04 |
Ingell Technologies Holding B.V. |
Biodegradable compositions suitable for controlled release
|
JP2014511687A
(ja)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
AU2012255913A1
(en)
|
2011-05-17 |
2013-11-21 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof for non-human vertebrates
|
US20140308363A1
(en)
|
2011-05-31 |
2014-10-16 |
Bind Therapeutics, Inc. |
Drug loaded polymeric nanoparticles and methods of making and using same
|
RS59037B1
(sr)
|
2011-06-08 |
2019-08-30 |
Translate Bio Inc |
Kompozicije lipidnih nanočestica i postupci za isporuku irnk
|
CN103748078B
(zh)
|
2011-06-08 |
2016-11-09 |
夏尔人类遗传性治疗公司 |
可裂解脂质
|
US8916696B2
(en)
|
2011-06-12 |
2014-12-23 |
City Of Hope |
Aptamer-mRNA conjugates for targeted protein or peptide expression and methods for their use
|
CA2840989A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic combination compositions and uses thereof
|
EP3508219A1
(en)
|
2011-07-06 |
2019-07-10 |
GlaxoSmithKline Biologicals S.A. |
Self-replicating rna prime - protein boost vaccines
|
SG10201605500TA
(en)
*
|
2011-07-06 |
2016-08-30 |
Novartis Ag |
Cationic oil-in-water emulsions
|
JP6018197B2
(ja)
|
2011-07-21 |
2016-11-02 |
クローダ インターナショナル パブリック リミティド カンパニー |
分枝状ポリエーテル−ポリアミドブロックコポリマー並びにそれらの製造方法及び使用方法
|
KR20140051357A
(ko)
|
2011-08-26 |
2014-04-30 |
애로우헤드 리서치 코오포레이션 |
In Vivo 핵산 전달용 폴리(비닐 에스테르) 고분자
|
US9126966B2
(en)
|
2011-08-31 |
2015-09-08 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use thereof
|
KR20140067070A
(ko)
|
2011-08-31 |
2014-06-03 |
말린크로트 엘엘씨 |
H-포스포네이트에 의한 나노입자 peg 개질
|
TWI570240B
(zh)
|
2011-09-09 |
2017-02-11 |
默沙東公司 |
作為細胞巨大病毒疫苗之條件式複製cmv
|
EP3384938A1
(en)
|
2011-09-12 |
2018-10-10 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
US20150017245A1
(en)
|
2011-09-22 |
2015-01-15 |
Bind Therapeutics, Inc. |
Methods of treating cancers with therapeutic nanoparticles
|
WO2013072929A2
(en)
|
2011-09-23 |
2013-05-23 |
Indian Institute Of Technology |
Nanop article based cosmetic composition
|
BR112014008694A2
(pt)
*
|
2011-10-11 |
2017-06-20 |
Novartis Ag |
moléculas de ácido nucleico policistrônico recombinante
|
WO2013054199A2
(en)
|
2011-10-12 |
2013-04-18 |
Novartis Ag |
Cmv antigens and uses thereof
|
EP3960726A1
(en)
|
2011-10-18 |
2022-03-02 |
Dicerna Pharmaceuticals, Inc. |
Amine cationic lipids and uses thereof
|
PE20150041A1
(es)
|
2011-10-27 |
2015-01-28 |
Massachusetts Inst Technology |
Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco
|
AU2012330819B2
(en)
|
2011-11-04 |
2017-08-31 |
Nitto Denko Corporation |
Single use system for sterilely producing lipid-nucleic acid particles
|
AU2012335277B2
(en)
|
2011-11-11 |
2018-06-14 |
Variation Biotechnologies Inc. |
Compositions and methods for treatment of cytomegalovirus
|
WO2013078199A2
(en)
|
2011-11-23 |
2013-05-30 |
Children's Medical Center Corporation |
Methods for enhanced in vivo delivery of synthetic, modified rnas
|
EP3988537A1
(en)
|
2011-12-07 |
2022-04-27 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
WO2013086373A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Lipids for the delivery of active agents
|
US20140343129A1
(en)
|
2011-12-14 |
2014-11-20 |
Moderna Therapeutics, Inc. |
Modified nucleic acids, and acute care uses thereof
|
EP2791364A4
(en)
|
2011-12-14 |
2015-11-11 |
Moderna Therapeutics Inc |
METHODS OF RESPONSE TO A BIOLOGICAL THREAT
|
EP2791160B1
(en)
|
2011-12-16 |
2022-03-02 |
ModernaTX, Inc. |
Modified mrna compositions
|
US20130165504A1
(en)
|
2011-12-21 |
2013-06-27 |
modeRNA Therapeutics |
Methods of increasing the viability or longevity of an organ or organ explant
|
WO2013096812A1
(en)
|
2011-12-23 |
2013-06-27 |
Genentech, Inc. |
Articles of manufacture and methods for co-administration of antibodies
|
EP3677678B1
(en)
|
2011-12-30 |
2024-01-31 |
Cellscript, Llc |
Making and using in vitro-synthesized ssrna for introducing into mammalian cells to induce a biological or biochemical effect
|
CN104936620B
(zh)
|
2012-01-19 |
2019-08-09 |
约翰霍普金斯大学 |
增强粘膜渗透的纳米粒子调配物
|
WO2013113325A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Negatively charged nucleic acid comprising complexes for immunostimulation
|
WO2013116126A1
(en)
|
2012-02-01 |
2013-08-08 |
Merck Sharp & Dohme Corp. |
Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
|
US9416090B2
(en)
|
2012-02-03 |
2016-08-16 |
Rutgers, The State University Of New Jersey |
Polymeric biomaterials derived from phenolic monomers and their medical uses
|
WO2013120052A1
(en)
|
2012-02-10 |
2013-08-15 |
E. I. Du Pont De Nemours And Company |
Preparation, purification and use of high-x diblock copolymers
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
WO2013126803A1
(en)
|
2012-02-24 |
2013-08-29 |
Protiva Biotherapeutics Inc. |
Trialkyl cationic lipids and methods of use thereof
|
US10322089B2
(en)
|
2012-03-14 |
2019-06-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Nanoparticles, nanoparticle delivery methods, and systems of delivery
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
WO2013151666A2
(en)
*
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of biologics and proteins associated with human disease
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
AU2013243951A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of secreted proteins
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
EA201492055A1
(ru)
*
|
2012-06-08 |
2015-11-30 |
Шир Хьюман Дженетик Терапис, Инк. |
ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ
|
RU2015103891A
(ru)
|
2012-07-06 |
2016-08-27 |
Новартис Аг |
Комплексы белков цитомегаловируса
|
CN116376983A
(zh)
|
2012-07-27 |
2023-07-04 |
希望之城 |
一种递送ul128复合体和预防cmv感染的mva疫苗
|
US9512456B2
(en)
|
2012-08-14 |
2016-12-06 |
Modernatx, Inc. |
Enzymes and polymerases for the synthesis of RNA
|
WO2014093924A1
(en)
|
2012-12-13 |
2014-06-19 |
Moderna Therapeutics, Inc. |
Modified nucleic acid molecules and uses thereof
|
MX2015005505A
(es)
|
2012-10-30 |
2016-01-08 |
Redvax Gmbh |
Vacunas basadas en particular recombinantes contra la infeccion de citomegalovirus humano.
|
EP2922554B1
(en)
|
2012-11-26 |
2022-02-23 |
ModernaTX, Inc. |
Terminally modified rna
|
EP2929034A4
(en)
|
2012-12-04 |
2016-06-22 |
Merck Sharp & Dohme |
VIRUS VECTORS WITH CONDITIONAL REPLICATION
|
ES2968649T3
(es)
*
|
2012-12-07 |
2024-05-13 |
Translate Bio Inc |
Nanopartículas lipídicas para la administración de ARNm en los pulmones
|
AU2013355258A1
(en)
|
2012-12-07 |
2015-06-11 |
Alnylam Pharmaceuticals, Inc. |
Improved nucleic acid lipid particle formulations
|
US20150315541A1
(en)
|
2012-12-13 |
2015-11-05 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for altering cell phenotype
|
ES2692363T3
(es)
|
2013-03-14 |
2018-12-03 |
Translate Bio, Inc. |
Composiciones terapéuticas de ARNm y su uso para tratar enfermedades y trastornos
|
CA2903880A1
(en)
*
|
2013-03-14 |
2014-09-25 |
Shire Human Genetic Therapies, Inc. |
Methods and compositions for delivering mrna coded antibodies
|
US20160032316A1
(en)
|
2013-03-14 |
2016-02-04 |
The Trustees Of The University Of Pennsylvania |
Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides
|
US10258698B2
(en)
|
2013-03-14 |
2019-04-16 |
Modernatx, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
EP3578663A1
(en)
|
2013-03-15 |
2019-12-11 |
ModernaTX, Inc. |
Manufacturing methods for production of rna transcripts
|
EP2983804A4
(en)
|
2013-03-15 |
2017-03-01 |
Moderna Therapeutics, Inc. |
Ion exchange purification of mrna
|
WO2014152030A1
(en)
|
2013-03-15 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Removal of dna fragments in mrna production process
|
WO2014144039A1
(en)
|
2013-03-15 |
2014-09-18 |
Moderna Therapeutics, Inc. |
Characterization of mrna molecules
|
EP2971161B1
(en)
|
2013-03-15 |
2018-12-26 |
ModernaTX, Inc. |
Ribonucleic acid purification
|
ES2967701T3
(es)
*
|
2013-03-15 |
2024-05-03 |
Translate Bio Inc |
Mejora sinergística de la entrega de ácidos nucleicos mediante formulaciones mezcladas
|
US20160017313A1
(en)
|
2013-03-15 |
2016-01-21 |
Moderna Therapeutics, Inc. |
Analysis of mrna heterogeneity and stability
|
CA2906732C
(en)
|
2013-03-15 |
2023-08-08 |
The University Of British Columbia |
Lipid nanoparticles for transfection and related methods
|
TW201515650A
(zh)
|
2013-05-06 |
2015-05-01 |
艾爾妮蘭製藥公司 |
遞送經脂質調配之核酸分子之劑量及方法
|
TW201534578A
(zh)
|
2013-07-08 |
2015-09-16 |
Daiichi Sankyo Co Ltd |
新穎脂質
|
WO2015011633A1
(en)
|
2013-07-23 |
2015-01-29 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for delivering messenger rna
|
SG11201510746WA
(en)
|
2013-08-21 |
2016-03-30 |
Curevac Ag |
Respiratory syncytial virus (rsv) vaccine
|
WO2015047901A1
(en)
|
2013-09-24 |
2015-04-02 |
Duke University |
Compositions, methods and kits for eliciting an immune response
|
US10385088B2
(en)
|
2013-10-02 |
2019-08-20 |
Modernatx, Inc. |
Polynucleotide molecules and uses thereof
|
EA201690675A1
(ru)
|
2013-10-03 |
2016-08-31 |
Модерна Терапьютикс, Инк. |
Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
|
CA2927393A1
(en)
|
2013-10-18 |
2015-04-23 |
Moderna Therapeutics, Inc. |
Compositions and methods for tolerizing cellular systems
|
MX2016005238A
(es)
|
2013-10-22 |
2016-08-12 |
Shire Human Genetic Therapies |
Formulaciones de lipidos para la administracion de acido ribonucleico mensajero.
|
PT3077519T
(pt)
|
2013-12-03 |
2021-05-13 |
Hookipa Biotech Ag |
Vacinas contra cmv
|
JP6679484B2
(ja)
|
2013-12-11 |
2020-04-15 |
ザ ヘンリー エム. ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド |
ヒトヘルペスウイルス三量体糖タンパク質B、三量体gBを含むタンパク質複合体、及びワクチンとしてのそれらの使用
|
WO2015095346A1
(en)
|
2013-12-19 |
2015-06-25 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
ES2774968T3
(es)
|
2013-12-19 |
2020-07-23 |
Novartis Ag |
Lípidos y composiciones lipídicas para la administración de agentes activos
|
WO2015110659A1
(en)
|
2014-01-27 |
2015-07-30 |
Bionor Immuno As |
Methods of immunization with a vaccine inducing a humoral immune response and with a vaccine inducing a cellular immune response
|
SI3122878T1
(sl)
|
2014-03-24 |
2019-05-31 |
Translate Bio, Inc. |
MRNA terapija za zdravljenje očesnih bolezni
|
WO2015165480A1
(en)
|
2014-04-30 |
2015-11-05 |
Institute For Research In Biomedicine |
Human cytomegalovirus vaccine compositions and method of producing the same
|
EP3134117A1
(en)
|
2014-04-23 |
2017-03-01 |
Institute for Research in Biomedicine |
Human cytomegalovirus vaccine compositions and method of producing the same
|
PT3134131T
(pt)
|
2014-04-23 |
2022-03-24 |
Modernatx Inc |
Vacinas de ácidos nucleicos
|
EP3139953A1
(en)
|
2014-05-08 |
2017-03-15 |
Pfizer Inc. |
Means and methods for treating cmv
|
AR100608A1
(es)
|
2014-05-27 |
2016-10-19 |
Glaxosmithkline Biologicals Sa |
Complejos de citomegalovirus y usos de los mismos
|
US10286086B2
(en)
|
2014-06-19 |
2019-05-14 |
Modernatx, Inc. |
Alternative nucleic acid molecules and uses thereof
|
CN106795096B
(zh)
|
2014-06-25 |
2020-05-29 |
爱康泰生治疗公司 |
用于递送核酸的新型脂质和脂质纳米颗粒制剂
|
CN114344275A
(zh)
|
2014-07-02 |
2022-04-15 |
川斯勒佰尔公司 |
信使rna的包封
|
US20170204152A1
(en)
|
2014-07-16 |
2017-07-20 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
JP2017523777A
(ja)
|
2014-07-17 |
2017-08-24 |
モデルナティエックス インコーポレイテッドModernaTX,Inc. |
ポリヌクレオチドの末端修飾
|
WO2016037053A1
(en)
|
2014-09-05 |
2016-03-10 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
EP3015475A1
(en)
|
2014-10-31 |
2016-05-04 |
Novartis AG |
Mammalian cells expressing cytomegalovirus antigens
|
EP3031822A1
(en)
|
2014-12-08 |
2016-06-15 |
Novartis AG |
Cytomegalovirus antigens
|
WO2016118724A1
(en)
|
2015-01-21 |
2016-07-28 |
Moderna Therapeutics, Inc. |
Lipid nanoparticle compositions
|
EP3048114A1
(en)
|
2015-01-22 |
2016-07-27 |
Novartis AG |
Cytomegalovirus antigens and uses thereof
|
EP3047856A1
(en)
|
2015-01-23 |
2016-07-27 |
Novartis AG |
Cmv antigens and uses thereof
|
CN108064304A
(zh)
|
2015-02-10 |
2018-05-22 |
俄勒冈健康与科学大学 |
可用于产生非典型cd8+ t细胞应答的方法和组合物
|
WO2016133881A1
(en)
|
2015-02-16 |
2016-08-25 |
Kamil Jeremy P |
Method of altering expression of alternative viral glycoprotein complexes
|
WO2016164762A1
(en)
|
2015-04-08 |
2016-10-13 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
|
US11559570B2
(en)
|
2015-05-15 |
2023-01-24 |
CureVac SE |
Prime-boost regimens involving administration of at least one mRNA construct
|
WO2016201377A1
(en)
|
2015-06-10 |
2016-12-15 |
Moderna Therapeutics, Inc. |
Targeted adaptive vaccines
|
US20180296663A1
(en)
|
2015-06-17 |
2018-10-18 |
Curevac Ag |
Vaccine composition
|
DK3313829T3
(da)
|
2015-06-29 |
2024-06-17 |
Acuitas Therapeutics Inc |
Lipider og lipide nanopartikelformuleringer til levering af nukleinsyrer
|
WO2017015463A2
(en)
|
2015-07-21 |
2017-01-26 |
Modernatx, Inc. |
Infectious disease vaccines
|
WO2017015457A1
(en)
|
2015-07-21 |
2017-01-26 |
Modernatx, Inc. |
Ebola vaccine
|
EP3328394A4
(en)
|
2015-07-30 |
2019-03-13 |
ModernaTX, Inc. |
PEPTIDE CONCATEMERIC EPITAOPE RNA
|
US20190008887A1
(en)
|
2015-07-30 |
2019-01-10 |
ModernaTX Inc. |
Multimeric mrna
|
US11564893B2
(en)
|
2015-08-17 |
2023-01-31 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
US20180237849A1
(en)
|
2015-08-17 |
2018-08-23 |
Modernatx, Inc. |
Rna mapping/fingerprinting
|
LT3350157T
(lt)
*
|
2015-09-17 |
2022-02-25 |
Modernatx, Inc. |
Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu
|
JP6990176B2
(ja)
|
2015-10-05 |
2022-02-03 |
モデルナティエックス インコーポレイテッド |
メッセンジャーリボ核酸薬物の治療投与のための方法
|
WO2017066789A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified sugar
|
AU2016341311B2
(en)
|
2015-10-22 |
2023-11-16 |
Modernatx, Inc. |
Respiratory syncytial virus vaccine
|
EP3364950A4
(en)
|
2015-10-22 |
2019-10-23 |
ModernaTX, Inc. |
VACCINES AGAINST TROPICAL DISEASES
|
HUE059127T2
(hu)
|
2015-10-22 |
2022-10-28 |
Modernatx Inc |
Légúti vírusok elleni vakcinák
|
CA3003090A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Cancer vaccines
|
BR112018008090A2
(pt)
|
2015-10-22 |
2018-11-13 |
Modernatx Inc |
vacina de vírus do herpes simplex.
|
CN109310751A
(zh)
|
2015-10-22 |
2019-02-05 |
摩登纳特斯有限公司 |
广谱流感病毒疫苗
|
WO2017070601A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Nucleic acid vaccines for varicella zoster virus (vzv)
|
AU2016342376A1
(en)
|
2015-10-22 |
2018-06-07 |
Modernatx, Inc. |
Sexually transmitted disease vaccines
|
WO2017070613A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
CA3201644A1
(en)
|
2015-10-28 |
2017-05-04 |
Acuitas Therapeutics, Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
AU2016366978B2
(en)
|
2015-12-10 |
2022-07-28 |
Modernatx, Inc. |
Compositions and methods for delivery of therapeutic agents
|
MA43568A
(fr)
|
2015-12-17 |
2018-11-14 |
Modernatx Inc |
Polynucléotides codant pour la méthylmalonyl-coa mutase
|
US10465190B1
(en)
|
2015-12-23 |
2019-11-05 |
Modernatx, Inc. |
In vitro transcription methods and constructs
|
US20210206818A1
(en)
|
2016-01-22 |
2021-07-08 |
Modernatx, Inc. |
Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
|
WO2017191274A2
(en)
|
2016-05-04 |
2017-11-09 |
Curevac Ag |
Rna encoding a therapeutic protein
|
AU2017268399B2
(en)
|
2016-05-18 |
2023-01-12 |
Modernatx, Inc. |
mRNA combination therapy for the treatment of cancer
|
EP3458108A4
(en)
|
2016-05-18 |
2020-04-22 |
ModernaTX, Inc. |
POLYNUCLEOTIDES FOR CODING THE TRANSMEMBRANE CONDUCTIVE REGULATOR OF CYSTIC FIBROSE FOR TREATING CYSTIC FIBROSE
|
CN115837014A
(zh)
|
2016-05-18 |
2023-03-24 |
摩登纳特斯有限公司 |
编码松弛素的多核苷酸
|
US20190382774A1
(en)
|
2016-05-18 |
2019-12-19 |
Modernatx, Inc. |
Polyribonucleotides containing reduced uracil content and uses thereof
|
EP3458106A4
(en)
|
2016-05-18 |
2020-03-18 |
Modernatx, Inc. |
POLYNUCLEOTIDES ENCODING LIPOPROTEIN LIPASE FOR THE TREATMENT OF HYPERLIPIDEMIA
|
MA45032A
(fr)
|
2016-05-18 |
2019-03-27 |
Fundacion Para La Investig Medica Aplicada |
Polynucléotides codant pour la porphobilinogène désaminase destinés au traitement de la porphyrie intermittente aiguë
|
JP7114485B2
(ja)
|
2016-05-18 |
2022-08-08 |
モデルナティエックス インコーポレイテッド |
ファブリー病の治療のためのα-ガラクトシダーゼAをコードするポリヌクレオチド
|
US11001861B2
(en)
|
2016-05-18 |
2021-05-11 |
Modernatx, Inc. |
Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
|
US20190298657A1
(en)
|
2016-05-18 |
2019-10-03 |
Modernatx, Inc. |
Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
|
WO2017201342A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding jagged1 for the treatment of alagille syndrome
|
SG11201810162PA
(en)
|
2016-05-18 |
2018-12-28 |
Modernatx Inc |
Polynucleotides encoding citrin for the treatment of citrullinemia type 2
|
WO2017208191A1
(en)
|
2016-06-02 |
2017-12-07 |
Glaxosmithkline Biologicals Sa |
Zika viral antigen constructs
|
JP2019525901A
(ja)
|
2016-06-14 |
2019-09-12 |
モデルナティエックス インコーポレイテッドModernaTX,Inc. |
脂質ナノ粒子の安定化製剤
|
CN109937253B
(zh)
|
2016-09-14 |
2023-06-30 |
摩登纳特斯有限公司 |
高纯度rna组合物及其制备方法
|
WO2018075980A1
(en)
|
2016-10-21 |
2018-04-26 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
CA3042015A1
(en)
|
2016-10-26 |
2018-05-03 |
Modernatx, Inc. |
Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
|
WO2018081462A1
(en)
|
2016-10-26 |
2018-05-03 |
Modernatx, Inc. |
Methods and compositions for rna mapping
|
EP3532094A1
(en)
|
2016-10-26 |
2019-09-04 |
CureVac AG |
Lipid nanoparticle mrna vaccines
|
WO2018089540A1
(en)
|
2016-11-08 |
2018-05-17 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
MA46766A
(fr)
|
2016-11-11 |
2019-09-18 |
Modernatx Inc |
Vaccin antigrippal
|
MA50335A
(fr)
|
2016-12-08 |
2020-08-19 |
Modernatx Inc |
Vaccins à acide nucléique contre des virus respiratoires
|
EP3555289A1
(en)
|
2016-12-13 |
2019-10-23 |
ModernaTX, Inc. |
Rna affinity purification
|
US20180243225A1
(en)
|
2017-01-25 |
2018-08-30 |
Modernatx, Inc. |
Ebola/marburg vaccines
|
JP2020506189A
(ja)
|
2017-02-01 |
2020-02-27 |
モデルナティーエックス, インコーポレイテッド |
Rna癌ワクチン
|
CN110430894A
(zh)
|
2017-02-01 |
2019-11-08 |
莫得纳特斯公司 |
编码活化致癌基因突变肽的免疫调节治疗性mrna组合物
|
EP3577221A4
(en)
|
2017-02-01 |
2020-12-23 |
ModernaTX, Inc. |
SECONDARY POLYNUCLEOTIDE STRUCTURE
|
EP3582790A4
(en)
|
2017-02-16 |
2020-11-25 |
ModernaTX, Inc. |
VERY POWERFUL IMMUNOGENIC COMPOSITIONS
|
US20200368162A1
(en)
|
2017-02-24 |
2020-11-26 |
Modernatx, Inc. |
Nucleic Acid-Based Therapy of Muscular Dystrophies
|
EP3595713A4
(en)
|
2017-03-15 |
2021-01-13 |
ModernaTX, Inc. |
RESPIRATORY SYNCYTIAL VIRUS VACCINE
|
RS63953B1
(sr)
|
2017-03-15 |
2023-02-28 |
Modernatx Inc |
Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava
|
WO2018170245A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
US11045540B2
(en)
|
2017-03-15 |
2021-06-29 |
Modernatx, Inc. |
Varicella zoster virus (VZV) vaccine
|
WO2018170256A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
US20200030432A1
(en)
|
2017-03-17 |
2020-01-30 |
Modernatx, Inc. |
Zoonotic disease rna vaccines
|
WO2018175783A1
(en)
|
2017-03-22 |
2018-09-27 |
Modernatx, Inc. |
Rna bacterial vaccines
|
MA48047A
(fr)
|
2017-04-05 |
2020-02-12 |
Modernatx Inc |
Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
|
MA49463A
(fr)
|
2017-04-26 |
2021-05-05 |
Modernatx Inc |
Vaccin contre le virus de l'herpès simplex
|
US11786607B2
(en)
|
2017-06-15 |
2023-10-17 |
Modernatx, Inc. |
RNA formulations
|
WO2018232355A1
(en)
|
2017-06-15 |
2018-12-20 |
Modernatx, Inc. |
Rna antibodies
|
CN111212905A
(zh)
|
2017-08-18 |
2020-05-29 |
摩登纳特斯有限公司 |
Rna聚合酶变体
|
EP3668979A4
(en)
|
2017-08-18 |
2021-06-02 |
Modernatx, Inc. |
METHOD OF HPLC ANALYSIS
|
US20200254086A1
(en)
|
2017-08-18 |
2020-08-13 |
Moderna TX, Inc. |
Efficacious mrna vaccines
|
US11866696B2
(en)
|
2017-08-18 |
2024-01-09 |
Modernatx, Inc. |
Analytical HPLC methods
|
US10653767B2
(en)
|
2017-09-14 |
2020-05-19 |
Modernatx, Inc. |
Zika virus MRNA vaccines
|
US20190192646A1
(en)
|
2017-11-03 |
2019-06-27 |
Modernatx, Inc. |
Salmonella vaccines
|
CA3083102A1
(en)
|
2017-11-21 |
2019-05-31 |
Modernatx, Inc. |
Epstein-barr virus vaccines
|
US11911453B2
(en)
|
2018-01-29 |
2024-02-27 |
Modernatx, Inc. |
RSV RNA vaccines
|
EP3813848A4
(en)
|
2018-06-27 |
2022-07-20 |
ModernaTX, Inc. |
EPITOPE SELECTION FOR PERSONALIZED CANCER VACCINE
|
US20220054653A1
(en)
|
2018-09-13 |
2022-02-24 |
Modernatx, Inc. |
Modified mrna for the treatment of progressive familial intrahepatic cholestasis disorders
|
EP3852732A1
(en)
|
2018-09-19 |
2021-07-28 |
ModernaTX, Inc. |
Peg lipids and uses thereof
|
JP7410135B2
(ja)
|
2018-09-19 |
2024-01-09 |
モデルナティエックス インコーポレイテッド |
治療薬の細胞内送達のための化合物及び組成物
|
WO2020061295A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
High-purity peg lipids and uses thereof
|
US20220125899A1
(en)
|
2018-11-07 |
2022-04-28 |
Modernatx, Inc. |
Rna cancer vaccines
|
JP2022521094A
(ja)
|
2019-02-20 |
2022-04-05 |
モデルナティエックス インコーポレイテッド |
共転写キャッピング用rnaポリメラーゼバリアント
|
MX2021011031A
(es)
|
2019-03-11 |
2021-12-10 |
Modernatx Inc |
Proceso de transcripción in vitro en lotes alimentados.
|
EP3938379A4
(en)
|
2019-03-15 |
2023-02-22 |
ModernaTX, Inc. |
HIV RNA VACCINE
|
JP2022535006A
(ja)
|
2019-05-31 |
2022-08-04 |
モデルナティエックス インコーポレイテッド |
増殖t細胞アッセイ
|
CN114269918A
(zh)
|
2019-08-14 |
2022-04-01 |
摩登纳特斯有限公司 |
用于纯化体外转录的下游产物的方法
|
CA3154082A1
(en)
|
2019-09-11 |
2021-03-18 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
CA3155014A1
(en)
|
2019-09-19 |
2021-03-25 |
Modernatx, Inc. |
Cap guides and methods of use thereof for rna mapping
|
WO2021142306A1
(en)
|
2020-01-10 |
2021-07-15 |
Modernatx, Inc. |
Variational autoencoder for biological sequence generation
|
US20210228707A1
(en)
|
2020-01-28 |
2021-07-29 |
Modernatx, Inc. |
Coronavirus rna vaccines
|
KR20220133911A
(ko)
|
2020-01-30 |
2022-10-05 |
모더나티엑스, 인크. |
호흡기 바이러스 면역화 조성물
|
AU2021215938A1
(en)
|
2020-02-07 |
2022-09-01 |
Modernatx, Inc. |
Sars-cov-2 mrna domain vaccines
|
WO2021211343A1
(en)
|
2020-04-13 |
2021-10-21 |
Modernatx, Inc. |
Zika virus mrna vaccines
|
WO2021222304A1
(en)
|
2020-04-27 |
2021-11-04 |
Modernatx, Inc. |
Sars-cov-2 rna vaccines
|
EP4149485A1
(en)
|
2020-05-15 |
2023-03-22 |
ModernaTX, Inc. |
Rna formulations for high volume distribution, and methods of using the same for treating covid-19
|
WO2021159130A2
(en)
|
2020-05-15 |
2021-08-12 |
Modernatx, Inc. |
Coronavirus rna vaccines and methods of use
|
WO2021237084A1
(en)
|
2020-05-21 |
2021-11-25 |
Modernatx, Inc. |
Methylene blue stabilized mrna compositions
|
CA3185855A1
(en)
|
2020-06-05 |
2021-12-09 |
Modernatx, Inc. |
Bacterial strains for dna production
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
EP4217371A1
(en)
|
2020-09-25 |
2023-08-02 |
ModernaTX, Inc. |
Multi-proline-substituted coronavirus spike protein vaccines
|